Transfection innovation for large scale AAV and LV – Considerations for process development through commercial manufacturing
Sponsor
Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
GMP-compliant nucleic acid delivery to HEK 293 cells is often a critical first step in the manufacture of advanced therapies utilizing recombinant adeno-associated virus (AAV) or lentivirus (LV) to facilitate delivery of a therapeutic transgene to patients. Accordingly, the need for safe and reproducible large-scale viral vector manufacture processes has never been greater. Mirus Bio has developed a fully synthetic, innovative transfection formulation to enable higher titer AAV and LV generation and reduce the cost of therapeutic development and manufacture to bring more life-changing doses to patients sooner.
- Optimization strategies for achieving higher AAV and LV titers via transient transfection workflows in both adherent and suspension HEK 293 cells.
- Key considerations for reagent selection and process development for a seamless transition from R&D scale to commercial manufacturing.
- How VirusGEN® GMP AAV and LV products enable significantly higher functional titers than PEI-derived polymers or liposomes alone.
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Precision in production: optimizing monitoring and quality control for high-value plasmids
Advancing cell therapy: innovations in polymer-based encapsulation and delivery
Pure and simple: understanding LNP analytics for better mRNA-based drugs
